- OptiNose has undertaken its IPO on Nasdaq.
- The company and its stockholders have raised $120.2 million.
- OptiNose has offered 2,875,000 shares for sale, while the other 2,875,000 were sold by selling stockholders.
- Jefferies and Piper Jaffray have acted as underwriters.
- OptiNose is a pharmaceutical company focused on treatments for ear, nose and throat allergies.
Katrin Kostadinova - Data analyst